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Liposome-based chemotherapeutics used in the treatment of breast cancer can in principle enhance the therapeutic index of
otherwise unencapsulated anticancer drugs. This is partially attributed to the fact that encapsulation of cytotoxic agents within
liposomes allows for increased concentrations of the drug to be delivered to the tumor site. In addition, the presence of the
phospholipid bilayer prevents the encapsulated active form of the drug from being broken down in the body prior to reaching
tumor tissue and also serves to minimize exposure of the drug to healthy sensitive tissue. While clinically approved liposome-
based chemotherapeutics such as Doxil have proven to be quite eﬀective in the treatment of breast cancer, signiﬁcant challenges
remain involving poor drug transfer between the liposome and cancerous cells. In this review, we discuss the recent advancements
made in the development of liposome-based chemotherapeutics with respect to improved drug transfer for use in breast cancer
therapy.
1.Introduction
A signiﬁcant challenge in the treatment of cancer involving
chemotherapy is the eﬃcient delivery of cytotoxic agents
to tumor tissue while at the same time minimizing the
u n d e s i r e dn e g a t i v es i d ee ﬀects associated with these drugs.
The use of drug delivery systems (DDSs) such as liposomes
can alter drug pharmacokinetics and biodistribution in a
manner that improves the overall pharmacological proper-
ties of commonly used chemotherapeutics. Liposomes are
particularlyattractiveDDSinpartduetotheeasewithwhich
they can be generated and modiﬁed such that they can be
used to treat a wide variety of cancers [1–3]. Breast cancer
in particular has been the focus of many studies involving
liposome-basedchemotherapeuticsinpartduetotheclinical
success of various drugs such as Doxil, which is a liposomal
formulation currently used to treat recurrent breast cancer
[4–6]. Doxil is a liposomal preparation composed of the
relatively high phase-transition temperature phospholipid
hydrogenated soy phosphatidylcholine (HSPC) and choles-
terol [7, 8] resulting in a stable DDS with enhanced
bilayer rigidity. The anthracycline doxorubicin is the active
cytotoxic agent and is contained within the internal aqueous
core of the liposome. The encapsulation of doxorubicin
within liposomes signiﬁcantly decreases the cardiotoxicity
that commonly results from the use of unencapsulated
anthracyclines by decreasing the amount of the drug being
delivered to the heart [9, 10]. Thus, patients can receive
much higher doses of the chemotherapeutic in the liposomal
formulation compared to unencapsulated, thereby allowing
tumor tissue to potentially be exposed to a lethal dose of
the drug while minimizing deleterious side eﬀects. This
inherent advantage associated with the use of liposomes as
drug delivery vehicles also serves to minimize the many
othertoxicsideeﬀectsassociatedwithdoxorubicintoinclude
gastrointestinal toxicity and complications arising from
myelosuppression [10, 11]. However, while liposome-based
drugs such as Doxil have proven to be eﬀective, signiﬁcant
challenges remain involving future improved formulations,
particularly with respect to drug transfer between the DDS
and cancerous cells. This review discusses the beneﬁts
and challenges associated with the use of liposome-based
chemotherapeutics in the treatment of breast cancer and
also addresses the recent advances made in the ﬁeld with
respect to improved formulations aimed to surmount some
of these obstacles. Amongst the strategies discussed here, we2 Journal of Drug Delivery
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Figure 1: Temperature-sensitive liposomes designed to remain stable while in circulation at 37◦C and become signiﬁcantly destabilized in
the tumor microenvironment at slightly higher temperatures 39–42◦C.
discuss designs intended to improve drug release within the
tumor microenvironment and/or colocalization between the
drug and breast cancer cells to include temperature-sensitive
liposomes and targeted liposomes.
2. Deliveryof Pegylated
Liposome-EncapsulatedDrugs
Liposomes have long been recognized as drug delivery
vehiclesforchemotherapeuticssincetheywereﬁrstdescribed
in the 1960s. They are well suited for this purpose as they
can accommodate both hydrophilic and hydrophobic drugs
by storing them either in their internal aqueous core or their
phospholipid bilayer, respectively. The mere fact that lipo-
somes are generated from phospholipids makes them ideal
candidates for drug delivery systems as they are nontoxic
and biodegradable. In addition to being biocompatible, the
phospholipid bilayer prevents the encapsulated active form
of the drug from being broken down in the body prior to
reaching tumor tissue and also minimizes exposure of the
encapsulateddrugtohealthytissuewhileincirculation. Both
of these eﬀects serve to increase the therapeutic indices of
drugs as elevated levels of the active form of the drug is
delivered to the tumor site such that the intended cytotoxic
eﬀectisachieved,whileatthesametimeunintendednegative
side eﬀects of the drug are substantially reduced when
compared to the unencapsulated form. For example, while
proving to be quite eﬃcient when used in clinical settings
to treat various types of cancers, liposomal treatment has
been shown to dramatically reduce some of the traditional
sideeﬀectsassociatedwithchemotherapy,suchasnauseaand
vomiting when compared to unencapsulated drugs [12].
An important physical aspect associated with the clinical
successes of liposome-based drugs is the overall size of
the nanocarrier. While the size of these drug delivery
systems can be carefully controlled, liposomes intended for
the delivery of chemotherapeutics tend to be ∼50–100nm in
diameter. This lower-size limit prevents these predominately
intravenous based drugs from randomly penetrating normal
vessel walls while in circulation. As far as the upper size
limit, it may appear as if larger systems would be ideal
based on the fact that more of the cytotoxic agent could
potentially be delivered to the tumor site; however, there
is an upper size limit to these systems. In order to gain
access to tumor tissue, it is imperative that these drugs retain
the ability to extravasate from circulation through the large
vascular defects known to be present in and around tumor
sites attributed to constant ongoing angiogenesis previously
reportedtobe ∼250nmorgreater[13].Therefore,liposome-
based chemotherapeutics whose overall size is below this
threshold have the potential to accumulate within tumor
tissue based on this form of “passive” drug delivery. This
coupled with the fact that drug retention within the tumor
is generally high attributed to the poor lymphatic drainage
observed within tumors results in a phenomenon known
as the enhanced permeation and retention (EPR) eﬀect
[14–16]. Another major limiting factor with respect to the
size of these drug delivery systems relates to circulation
times in vivo. The general trend for liposomes of similar
phospholipid compositions is that increasing size results in
escalating uptake by the reticuloendothelial system (RES)
[17]. In fact, previous studies have shown that liposomes
250nm in diameter are removed more than twice as fast
from circulation when compared to liposomes 100nm in
diameter of similar phospholipid compositions [18]. This
is particularly problematic as it is imperative that these
systems remain in circulation long enough such that they
can accumulate within tumor tissue at levels great enough to
have the intended cytotoxic eﬀect. One obvious method for
overcoming this obstacle involves the overall size reduction
of the nanocarrier, which as mentioned earlier also has
the unfortunate eﬀect of translating into less drug being
delivered by the nanocarrier. Another proven method forJournal of Drug Delivery 3
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Figure 3: Both estradiol (a) and estrone (b) have previously been used as targeting ligands in liposome-based chemotherapeutics against
breast cancer.
overcoming this obstacle without compromising the amount
of chemotherapeutic being delivered to tumors is the surface
coating of these drug delivery vehicles with polymers, par-
ticularly polyethylene glycol (PEG). This generates “Stealth”
liposomes, which is a name given to them based on their
ability to evade the immune system resulting in signiﬁcant
increases in circulations times in vivo [14, 19, 20]. In fact, the
beneﬁt of pegylation is quite apparent when comparing the
relative half-lives of nonpegylated and pegylated liposomes
w h i c hi n c r e a s e sf r o mj u s taf e wh o u r st oa sm u c ha s4 5
hours, respectively [9]. Therefore, it is not surprising to note
that the clinically approved drug Doxil is in fact pegylated
(Mr 2000) in order to improve tumor site accumulation
of the drug [14]. However, while surface coating liposomes
with PEG achieve desirable circulation times in vivo,i t
also negatively inﬂuences tumor cellular uptake of these
systems as the presence of the PEG moiety presents a steric
barrier between the drug and cancer cells [10]. Therefore,
while pegylation does not eliminate cellular uptake entirely,
delivery of pegylated liposome-based chemotherapeutics is
in large part based on the ability of the encapsulated drug
to escape or be released from the nanocarrier via leakage in
the tumor microenvironment prior to tumor cellular uptake
of the free drug. Therefore, future strategies involving the
improved delivery eﬃciency of pegylated liposome-based
drugs, particularly in the treatment of breast cancer, are
aimed at various enhanced triggered release techniques to
facilitate this process. One such method involves the heat-
triggered release of pegylated thermosensitive liposomes.
2.1. Hyperthermia and Improved Liposome-Based Drug Deliv-
ery. While liposome-based drugs of the appropriate size
retain the ability to extravasate out of circulation at tumor
sites, various challenges remain involving release of the
encapsulated drug from the nanocarrier. Therefore, one
aspect with respect to the future design of these drugs4 Journal of Drug Delivery
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Figure 4: Structure of the tetrasaccharide Sialyl Lewis X used in the carbohydrate vector (which includes a spacer and membrane anchor)
to target lectins known to be overexpressed by mammalian malignant cells when compared to normal.
involves the incorporation of various molecules within
liposomal formulations that respond to external stimuli in
a manner that disrupts liposomes to allow for the delivery of
encapsulated material. While there have been many methods
reported recently aimed to accomplish this in order to
treat a wide variety of cancers, thermosensitive molecules
added to these formulations speciﬁcally for the purposes
of treating breast cancer have proven to be quite eﬀective.
These temperature-sensitive liposomes are designed to be
stable at the normal physiological temperature of 37◦Cb u t
become signiﬁcantly destabilized at slightly higher temper-
atures (Figure 1). The use of liposomes as the nanocarrier
in these formulations is a particularly attractive option
with respect to both enhanced tumor site accumulation,
as well as facilitated release of the encapsulated drug.
This is attributed to the fact that a local increase in
temperature has been shown to enhance extravasation of
liposomes out of circulation resulting in their preferential
accumulation to the heated tumor [21], and that liposomes
are known to become destabilized at elevated temperatures
[1, 2]. For example, we and others have previously shown
that liposomes composed of various phospholipids are
much leakier at 37◦C than those stored at 4◦C[ 1, 3,
22]. Thus, the use of temperature-sensitive liposomes to
deliverencapsulatedchemotherapeuticstosolidtumorssuch
as breast cancer is an area of promising research, and
many successful constructs have previously been reported.
For example, liposomes composed of dipalmitoylphos-
phatidylcholine (DPPC), monostearoylphosphatidylcholine
(MSPC), and distearoylphosphatidylethanolamine (DSPE)-
PEG 2000 are currently in Phase II clinical trials for the treat-
ment of recurrent breast cancer (http://www.celsion.com).
These lyso-lipid temperature-sensitive liposomes encapsu-
late doxorubicin and have previously been shown to exhibit
enhanced drug release rates under mild hyperthermic con-
ditions while remaining relatively stable at normal physio-
logical temperature [23]. More recently, Tagami et al. have
reportedasimilarliposome-basedsysteminwhichtheminor
component MSPC is replaced with a nonionic surfactant
Brij78 [24]. This new formulation outperformed the lyso-
lipid temperature-sensitive liposomes when tested in mice
inoculated with a mammary carcinoma cell line (EMT-6).
Chen et al. have also reported promising results using ther-
mosensitive liposomes prepared with DPPC, 1-myristoyl-
2-palmitoyl phosphatidylcholine (MPPC), and DSPE-PEG
2000 [25].
2.2. Targeted Liposome-Based Chemotherapeutics. Another
strategy employed in order to potentially increase the
overall therapeutic index of liposome-based drugs involves
improving the colocalization between the chemotherapeutic
and breast cancer cells. In some cases, this strategy may
also involve improvement of cellular internalization of the
whole liposome-based drug, particularly when cell-surface
receptors known to undergo receptor-mediated endocyto-
sis is concerned. Generally, these types of formulations
involve surface modiﬁcations made to liposomes in order to
accommodate targeting ligands which are speciﬁc for known
upregulated breast cancer cell-surface receptors (Figure 2),
andseveralpromisingconstructshaverecentlybeenreported
(Table 1). For example, anti-HER2 immunoliposomes have
been shown to be far more eﬀective against HER2-
overexpressing breast cancer cells when compared to nontar-
geted liposomes [26]. In this study, the targeted liposomes
were formulated with Fab of recombinant humanized anti-
HER2 monoclonal antibody. Immunoliposomes containing
anti-transferrin receptor antibody and loaded with siRNA
have been successfully used in breast cancer animal models
[28]. Similarly, siRNA-loaded liposomes surface modiﬁed
to contain a peptide which preferentially binds a speciﬁc
breast cancer cell line have recently been shown to exhibit
notable targeting capabilities [27]. A particularly attractive
target with respect to breast cancer is the estrogen receptor
(ER) which is overexpressed in a large number of breast
cancer cells [32, 33]. For example, estradiol has previously
been incorporated into liposomes for use as a targeting
ligand against ER-expressing breast cancer cells [29]. More
recently, Paliwal et al. have reported a targeted liposomal-Journal of Drug Delivery 5
Table 1: Recently reported targeted liposome-based chemotherapeutics to treat breast cancer. PE38KDEL from reference [26]i sa3 8k D a
mutant form of pseudomonas exotoxin A (PE), and the peptide sequence from reference [27]i sD M P G T V L P .
Cell-surface target Targeting ligand Encapsulated cargo Reference
HER2 Anti-HER2 Fab’ PE38KDEL [26]
Transferrin receptor Antitransferrin receptor antibody HER-2 siRNA [28]
MCF-7 cell speciﬁc Peptide PRDM14 siRNA [27]
Estrogen receptor 17β-estradiol Anticancer gene [29]
Estrogen receptor Estrone Doxorubicin [30]
Lectins Selectin ligand (SiaLeX) Merphalan [31]
based chemotherapeutic which utilizes a structurally similar
molecule, estrone instead of estradiol (Figure 3) as the tar-
geting ligand [30]. The tumor accumulation of the targeted
liposomes in this latter and most recent study was approxi-
mately 6 times higher than the observed accumulation with
nontargeted liposomes. Targeted liposomes have also been
generated using a speciﬁc carbohydrate vector, which have
been shown to have enhanced tumor growth inhibition
compared to their nontargeted counterparts when tested in
vivo in a mouse breast cancer model [31]. In this study,
aS i a L e X vector was used as the targeting ligand which targets
lectins, speciﬁc carbohydrate-binding proteins known to
be overexpressed by mammalian malignant cells when
compared to normal. The vector construct was designed to
essentially contain three parts for liposome incorporation
to include Sialyl Lewis X (Figure 4), a spacer, as well as a
membrane anchor.
3. Conclusions
The major overall goal in the design of liposome-based
chemotherapeutics is to generate a formulation that is stable
while in circulation, yet eﬃciently deliver encapsulated cyto-
toxic agents to tumor tissue. Currently, clinically approved
drugs to treat breast cancer such as Doxil are relatively stable
in circulation; however, drug transfer from the nanocarrier
to breast cancer cells remains particularly problematic. This
is in part attributed to the fact that DDSs of this size
(∼100nmindiameter)requirepegylationtoachieveoptimal
circulation times in vivo, which negatively inﬂuences cellular
uptake of these systems. One solution to this problem
involves making liposomes smaller in size. For example,
other clinically approved liposome-based drugs such as
DaunoXome currently used to treat Kaposi’s sarcoma do not
need to be pegylated as a result of their small size reported
to be ∼45nm in diameter [34]. An additional advantage
that smaller DDS may have over their larger counterparts
also involves their ability to potentially penetrate deeper
into the tumor microenvironment [35]. However, it remains
controversial as such small systems are potentially limited
in their ability to deliver an eﬀective dose of the drug to
tumor tissue. Thus, several groups are currently working
on improved formulations that retain adequate circulation
times in vivo,y e tm o r ee ﬃciently deliver their encapsulated
cargo without having to necessarily reduce the overall size of
the nanocarrier. Many of these systems have been reported
here and include formulations designed to release encap-
sulated cytotoxic agents at elevated temperatures and/or
improve colocalization between the drug and breast cancer
cells through targeting ligand addition. It is worth noting
that liposomal formulations involving both targeting ligand
incorporation as well as pegylation can be particularly
challenging as the presence of the PEG moiety has the
ability to potentially negatively inﬂuence receptor/ligand
recognition [3]. Nonetheless, the systems reported here or
similarformulationsmayinfactbecommonlyusedclinically
in the near future in order to more eﬀectively treat breast
cancer.
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